Sugi Predict

Sugi Predict / Compounds / SCHEMBL20288191

SCHEMBL20288191

SCHEMBL20288191

COC(=O)c1ccc(N)c(NCC2CCO2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.46
▸ PTGER4 P35408 2/20 0.46
▸ HDAC1 Q13547 1/20 0.45
▸ LNPEP Q9UIQ6 5/20 0.45
▸ ERAP2 Q6P179 2/20 0.45
▸ ALDH1A1 P00352 7/20 0.44
▸ KDM4E B2RXH2 6/20 0.44
▸ HSD17B10 Q99714 4/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ HPGD P15428 4/20 0.43
▸ MAPT P10636 4/20 0.43
▸ GAA P10253 2/20 0.43
▸ GLA P06280 1/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ CASP7 P55210 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ HCAR3 P49019 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29825443 1.00 KMT2A (0.46) KMT2APTGER4HDAC1LNPEPERAP2
SCHEMBL20280069 1.00 KMT2A (0.46) KMT2APTGER4HDAC1LNPEPERAP2
SCHEMBL29491456 1.00 KMT2A (0.46) KMT2APTGER4HDAC1LNPEPERAP2
SCHEMBL23286797 0.94 KMT2A (0.55) KMT2AALDH1A1KDM4EHSD17B10L3MBTL1
SCHEMBL24900222 0.94 KMT2A (0.55) KMT2AALDH1A1KDM4EHSD17B10L3MBTL1
SCHEMBL24900028 0.94 KMT2A (0.55) KMT2AALDH1A1KDM4EHSD17B10L3MBTL1
SCHEMBL24900139 0.93 KMT2A (0.51) KMT2APTGER4HDAC1ALDH1A1KDM4E
SCHEMBL30537054 0.90 PTGER4 (0.58) KMT2APTGER4LNPEPERAP2ALDH1A1
SCHEMBL24306327 0.90 PTGER4 (0.58) KMT2APTGER4LNPEPERAP2ALDH1A1
SCHEMBL29052950 0.90 PTGER4 (0.58) KMT2APTGER4LNPEPERAP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497382-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2025-12-16 — — US disclosed
US-20250099431-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2025-03-27 — — US disclosed
EP-4523751-A2 GLP-1R MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2025-03-19 — — EP disclosed
EP-4097097-B1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-01-15 — — EP disclosed
US-12121511-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2024-10-22 — — US disclosed
US-20240246959-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2024-07-25 — — US disclosed
CN-115515956-B Benzimidazole derivative, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-06-25 — — CN disclosed
CN-115279750-B GLP-1 receptor agonist, pharmaceutical composition containing same and preparation method thereof 株式会社LG化学 2024-06-21 — — CN disclosed
CN-115461334-B Benzimidazole derivative, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-06-21 — — CN disclosed
US-11981666-B2 GLP-1 receptor agonist and composition and use thereof HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) 2024-05-14 — — US disclosed
WO-2021154796-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2021-08-05 — — WO disclosed
WO-2021154796-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2021-08-05 — — WO disclosed
US-20210171499-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2021-06-10 — — US disclosed
US-20210171499-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2021-06-10 — — US disclosed
WO-2021081207-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2021-04-29 — — WO disclosed
WO-2021081207-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2021-04-29 — — WO disclosed
US-20200407347-A1 GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS ELI LILLY AND COMPANY 2020-12-31 — — US disclosed
WO-2020263695-A1 GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2020-12-30 — — WO disclosed
WO-2020234726-A1 COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES PFIZER INC. (US) 2020-11-26 — — WO disclosed
WO-2018109607-A1 GLP-1 RECEPTOR AGONISTS AND USES THEREOF PFIZER INC. (US) 2018-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246959-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GLP1R, GIPR, GCGR KMT2A 3588/4885PTGER4 1187/4885HDAC1 1318/4885
US-12121511-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 KMT2A 3755/4885PTGER4 948/4885HDAC1 1388/4885
US-20250099431-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 KMT2A 3755/4885PTGER4 948/4885HDAC1 1388/4885
US-11981666-B2 GLP-1 receptor agonist and composition and use thereof GLP1R, GIPR, GCGR KMT2A 3549/4885PTGER4 288/4885HDAC1 3055/4885
US-20200407347-A1 GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS GLP1R, GCGR, GIPR KMT2A 1997/4885PTGER4 1972/4885HDAC1 3665/4885
US-20210171499-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 KMT2A 3870/4885PTGER4 996/4885HDAC1 1434/4885
US-12497382-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 KMT2A 3870/4885PTGER4 996/4885HDAC1 1434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.